WO2010151697A1 - Method for treating a patient in need of aspirin therapy - Google Patents
Method for treating a patient in need of aspirin therapy Download PDFInfo
- Publication number
- WO2010151697A1 WO2010151697A1 PCT/US2010/039864 US2010039864W WO2010151697A1 WO 2010151697 A1 WO2010151697 A1 WO 2010151697A1 US 2010039864 W US2010039864 W US 2010039864W WO 2010151697 A1 WO2010151697 A1 WO 2010151697A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- aspirin
- unit dosage
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing a non-steroidal anti inflammatory drug ("NSAID") -associated ulcer by administering to the patient in need thereof a pharmaceutical composition in unit dosage form comprising aspirin, or a pharmaceutically acceptable salt thereof, and an acid inhibitor to the at risk patient and thereby decreasing the patient's risk of developing an ulcer.
- NSAID non-steroidal anti inflammatory drug
- Aspirin is an NSAID, and is the general name for acetylsalicylic acid. Aspirin is used to reduce fever and provide pain relief from conditions such as muscle aches, toothaches, common colds, and headaches. It may also be used to reduce pain and inflammation in conditions such as arthritis, rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis. Aspirin is also an anti-coagulant, and low-dose aspirin is often used to reduce blood clots that may lead to cardiovascular disease, including heart attack and stroke. In addition to its preventative use, it is also used in treatment of cardiovascular diseases. Low-dose aspirin is recommended for the prevention of cardiovascular and cerebrovascular events, and an estimated 50 million people in the United States take aspirin for cardioprotection.
- Aspirin is a potent inhibitor of thromboxane A2 ("TxA2") synthesis by platelets, reducing their aggregation and adhesion and thus reducing the risk of arterial thrombosis (Awtry, et al, Circulation 707:1206-1218 (2000); Gengo, et al, J. Clin. Pharmacol. 45:335-343 (2008)).
- TxA2 thromboxane A2
- This cardioprotective benefit of aspirin is not realized with antiplatelet drugs until platelet TxA2 generation is reduced by more than 95% in serum (Patrono, et al, New Eng. J. Med. 555:2373-2382 (2005); Grosser, et al.
- UGI mucosal injury includes petechia, erosions and ulcers.
- acid has the ability to impair normal hemostasis and healing.
- UGI effects of NSAIDs also include: dyspepsia (experienced by up to 40% of patients on NSAID therapy), erosive esophagitis ("EE") (experienced by 21% of regular NSAID users), and an increase in gastroesophageal reflux disease symptoms.
- dyspepsia experienced by up to 40% of patients on NSAID therapy
- EE erosive esophagitis
- the present disclosure is based upon the discovery of an aspirin combination treatment that reduces the risks associated with aspirin therapy, for example undesirable gastrointestinal side effects and other safety concerns, particularly during chronic treatment.
- the treatment involves the administration of a single, coordinated, unit dosage form that combines: a) an acid inhibitor that raises intragastric pH levels; and b) aspirin that is specially formulated to be released in a coordinated way with the acid inhibitor, such that administration of the unit dosage form reduces the risks associated with aspirin therapy, for example any adverse effects the aspirin may have on gastroduodenal mucosa.
- Either short- or long-acting acid inhibitors can be effectively used in the unit dosage forms disclosed herein.
- this treatment has the added benefit of being able to protect patients from other gastrointestinal ulcerogens whose effect may otherwise be enhanced by the disruption of gastroprotective prostaglandins due to aspirin therapy.
- the disclosure is directed to preventing or treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administration of the pharmaceutical compositions in unit dosage form disclosed herein.
- administration of the pharmaceutical compositions in unit dosage form disclosed herein to treat a disease or disorder in a patient at risk of developing an NSAID- associated ulcer decreases the risk of the patient developing an ulcer, including but not limited to decreasing the risk of the occurrence of a gastroduodenal ulcer or a duodenal ulcer.
- administration of the pharmaceutical compositions in unit dosage form disclosed herein to treat a disease or disorder in a patient at risk of developing an NSAID-associated ulcer reduces the patient's heartburn associated symptoms.
- administration of the pharmaceutical compositions in unit dosage form disclosed herein to treat a disease or disorder in a patient at risk of developing an NSAID-associated ulcer reduces the patient's dyspepsia associated symptoms.
- administration of the pharmaceutical compositions in unit dosage form disclosed herein to treat a disease or disorder in a patient at risk of developing an NSAID-associated ulcer reduces the patient's level of urinary 11-dehydrothromboxane.
- the disclosure is directed to preventing or treating a disease or disorder in a patient in need thereof wherein the disease or disorder is pain, inflammation, arthritis osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, headache, toothache, common cold, muscle ache, cardiovascular disease, cancer, cerebrovascular disease, or combinations thereof
- the pharmaceutical composition in unit dosage form administered to the patient comprises: a) a therapeutically effective amount of an acid inhibitor in an amount sufficient to raise the gastric pH of the patient to at least about 3.5, 4.0, 4.5, 5.0, 5.5, or higher upon administration of one or more of the unit dosage forms, and b) a therapeutically effective amount of aspirin, or a pharmaceutically acceptable salt thereof; wherein the aspirin, or a pharmaceutically acceptable salt thereof, is released from the unit dosage form only when the pH of the surrounding medium or environment is about 3.5, 4.0, 4.5, 5.0, 5.5 or higher.
- the pharmaceutical composition in unit dosage form comprises a) a therapeutically effective amount of an acid inhibitor that is immediately soluble when the dosage form is place in an aqueous medium, independent of pH, for example in an amount effective to raise the gastric pH of the patient to at least about 3.5, 4.0, 4.5, 5.0, 5.5, or higher upon administration of one or more of the unit dosage forms.
- the pharmaceutical composition in unit dosage form comprises a) an acid inhibitor in an amount effective to raise the gastric pH of the patient to at least 3.5, 4.0, 4.5, 5.0, 5.5, or higher upon administration of one or more of the unit dosage forms.
- the pharmaceutical composition in unit dosage form comprises b) a therapeutically effective amount of aspirin, or a pharmaceutically acceptable salt thereof; wherein the aspirin or a pharmaceutically acceptable salt thereof is surrounded by a coating that is substantially insoluble in an aqueous medium at a pH below about 3.5, 3.0, 2.5, 2.0, 1.5, or lower.
- the pharmaceutical composition in unit dosage form comprises b) aspirin or a pharmaceutically acceptable salt thereof, wherein the aspirin or a pharmaceutically acceptable salt thereof is released from the unit dosage form only when the pH of the surrounding medium or environment is about 3.5, 4.0, 4.5, 5.0, 5.5, or higher.
- the aqueous medium is also at a temperature of about 37°C.
- a therapeutically effective amount of an acid inhibitor is an amount sufficient to raise the gastric pH of the patient to at least about 3.5
- the unit dosage form provides for coordinated release of the acid inhibitor and the aspirin such that: i) at least a portion of the acid inhibitor is released independent of the pH of the surrounding medium or environment; and ii) the aspirin, or a pharmaceutically acceptable salt thereof, is not released from the unit dosage form until the pH of the surrounding medium is 3.5, 4.0, 4.5, 5.0, 5.5, or higher.
- the pharmaceutical composition in unit dosage form comprises any mixture of the above described acid inhibitor and aspirin, or a pharmaceutically acceptable salt thereof.
- the risk of NSAID-associated gastrointestinal ulcer in a patient may be associated with short-term or chronic NSAID treatment, age of the patient (for example if the patient is 50 years of age or older), or a combination thereof.
- a pharmaceutical composition in unit dosage form is administered to the patient for 7 days, 10 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 12 months, 18 months, or longer.
- a pharmaceutical composition in unit dosage form is administered to the patient frequently or chronically.
- the pharmaceutical composition in unit dose form disclosed herein decreases the risk of the patient developing a gastric ulcer, duodenal ulcer, or both.
- the disease or disorder treated by the pharmaceutical compositions disclosed herein include but are not limited to pain, inflammation, arthritis, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, headache, toothache, common cold, muscle ache, cardiovascular disease, cancer (e.g., colon cancer) or any combination thereof.
- the pharmaceutical composition in unit dose form disclosed herein may be administered to prevent or treat cardiovascular disease or cerebrovascular disease.
- the pharmaceutical composition in unit dose form disclosed herein may be administered to prevent or treat cancer, including but not limited to biliary tract cancer; brain cancer; breast cancer; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; fibrosarcoma, gastric cancer; hepatoma, intraepithelial neoplasms; lymphomas; liver cancer; lung cancer (e.g., small cell and non-small cell); melanoma; neuroblastomas; oral cancer; ovarian cancer; pancreatic cancer; prostate cancer; rectal cancer; sarcomas; skin cancer; testicular cancer; thyroid cancer; renal cancer, glioblastoma, adenocarcinoma, adenoma, astrocytoma, bladder tumor, bone carcinoma, brain carcinoma, Burkitt lymphoma, Kaposi Sarcoma, non-Hodgkins lymphoma, Hodgkins lymphoma, gastric tumor, breast carcinoma,
- cancer including
- the pharmaceutical compositions in unit dosage form disclosed herein may comprise an acid inhibitor in an amount effective to raise the pH of the gastric fluid of a patient to at least 3.5, at least 4.0, at least 4.5, at least 5.0, at least 5.5 or greater when the dosage form is administered to the patient, for example orally administered.
- the acid inhibitor may be present in the unit dosage form in an amount of from about 5 mg to about 1000 mg.
- the acid inhibitor is omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, dexlansoprazole, and tenatoprazole, or pharmaceutically acceptable salts thereof.
- the pharmaceutical compositions in unit dosage forms disclosed herein comprise omeprazole, or a pharmaceutically acceptable salt thereof, in an amount of, for example, about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, or 100 mg.
- the pharmaceutical compositions in unit dosage forms disclosed herein comprise aspirin, or a pharmaceutically acceptable salt thereof, in an amount of, for example, from about 30 mg to about 1300 mg, or at an amount of about 75 mg, 81 mg, 100 mg, 150 mg, 162 mg, 300 mg, 325 mg, 500 mg, or 650 mg.
- the pharmaceutical composition is formulated for administration to a patient one or more times daily.
- the unit dosage form is suitable for oral administration.
- the unit dosage form may be a tablet, a sequential-delivery tablet formulation, a capsule, a capsule containing beads or minitablets.
- the unit dosage form is a tablet comprising a core and two or more layers, in which i) the core comprises aspirin or a pharmaceutically acceptable salt thereof; ii) a first layer surrounds the core and the layer is a coating that is substantially insoluble in aqueous medium at a pH below 3.5, for example below 3.0, 2.5, 2.0, 1.5, 1.0, or lower and/or at a temperature of about 37°C; and iii) at least one second layer surrounds the first layer and comprises the acid inhibitor.
- the first layer may be, for example, an enteric coating ("EC") or a time-release coating.
- the unit dosage form may be further surrounded by a pharmacologically inert, water soluble coating or film.
- the administration of the unit dosage form disclosed herein improves compliance in a patient who requires short-term or chronic daily dosages of aspirin or a pharmaceutically acceptable salt thereof.
- administering a pharmaceutical composition in unit dosage form to a patient is more effective at decreasing the risk of developing an ulcer than treatment with only aspirin, for example enteric-coated or non-enteric-coated aspirin, or a pharmaceutically acceptable salt thereof.
- administering a pharmaceutical composition in unit dosage form disclosed herein to a patient reduces the patient's heartburn associated symptoms more than treating the patient in need thereof with only aspirin, for example enteric coated or non-enteric coated aspirin, or a pharmaceutically acceptable salt thereof.
- administering a pharmaceutical composition in unit dosage form disclosed herein to a patient reduces the patient's dyspepsia more than treating the patient in need thereof with only aspirin, for example enteric coated or non-enteric coated aspirin, or a pharmaceutically acceptable salt thereof.
- administering a pharmaceutical composition in unit dosage form disclosed herein to a patient reduces the patient's level of urinary 11- dehydrothromboxane more than treating the patient in need thereof with only aspirin, for example enteric coated or non-enteric coated aspirin, or a pharmaceutically acceptable salt thereof.
- Another embodiment of the present disclosure is a solid pharmaceutical composition in unit dosage form suitable for oral administration to a mammal, comprising: a) omeprazole or pharmaceutically acceptable salt thereof that is immediately soluble when the dosage form is placed in an aqueous medium, independent of pH; and b) aspirin or a pharmaceutically acceptable salt thereof, surrounded by a coating that is substantially insoluble in an aqueous medium at a pH below 3.5 and/or at a temperature of about 37°C.
- the omeprazole or pharmaceutically acceptable salt thereof is present in the composition in an amount effective to raise the pH of the gastric fluid of a mammal to at least about 3.5, 4.0, 4.5, 5.0, 5.5 or higher when the dosage form is administered orally to the mammal.
- the amount of aspirin, or a pharmaceutically acceptable salt thereof is about 75 mg, 81 mg, 100 mg, 150 mg, 162 mg, 300 mg, 325 mg, 500 mg, or 650 mg.
- the amount of omeprazole, or a pharmaceutically acceptable salt thereof is about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, or 100 mg.
- the solid pharmaceutical composition in unit dosage form may be formulated to be administered to a patient one or more times daily.
- the solid pharmaceutical composition in unit dosage form is suitable for oral administration.
- the solid pharmaceutical composition in unit dosage form may be a tablet, a sequential-delivery tablet formulation, a capsule, a capsule containing beads or minitablets.
- the solid pharmaceutical composition in unit dosage form is a tablet comprising a core and two or more layers, in which i) the core comprises aspirin or a pharmaceutically acceptable salt thereof; ii) a first layer surrounds the core and the layer is a coating that is substantially insoluble in aqueous medium at a pH below 3.5, for example below 3.0, 2.5, 2.0, 1.5, 1.0, or lower and/or at a temperature of about 37°C; and iii) at least one second layer surrounds the first layer and comprises omeprazole or pharmaceutically acceptable salt.
- the first layer may be, for example, an enteric coating ("EC") or a time-release coating.
- the solid pharmaceutical composition in unit dosage form may be further surrounded by a pharmacologically inert, water soluble coating or film.
- Figure 1 illustrates pooled gastroduodenal data from three Phase I studies on PA32520 and PA32540. Further information regarding Figure 1 may be found below in Example 1.
- Figure 2 illustrates the change in urinary l l-dh-TXB 2 at Day 28 in a Phase I study on PA32520. Further information regarding Figure 2 may be found below in Example 2.
- Figure 3 shows a release profile of PA32540 and is described more fully below in Example 3.
- the term "acid inhibitor” includes without limitation proton pump inhibitors and histamine H 2 receptor antagonists.
- proton pump inhibitors include but are not limited to omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, dexlansoprazole, and tenatoprazole.
- histamine H 2 receptor antagonists include but are not limited to cimetidine, ranitidine, ebrotidine, pabutidine, lafutidine, loxtidine, nizatidine, and famotidine.
- the term "at risk patient” refers to patient(s) at risk for NSAID associated ulcer due to age > 50 years, or a patient who has a history of UGI ulcer or bleeding.
- the at risk patient is a patient at risk for NSAID associated ulcer due to age greater than or equal to 50 years.
- the at risk patient is a patient at risk for NSAID associated ulcer due to history of UGI ulcer or bleeding.
- enantiomerically pure refers to a compound containing at least about 75% of the named enantiomer out of the total amount of the two possible enantiomers contained therein.
- enantiomerically pure refers to a compound containing at least about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 99.9% of the named enantiomer out of the total amount of the two possible enantiomers contained therein.
- pharmaceutically acceptable indicates the subject matter being identified as “pharmaceutically acceptable” is suitable and physiologically acceptable for administration to a patient/subject.
- pharmaceutically acceptable salt(s) denotes suitable and physiologically acceptable salt(s).
- aspirin or pharmaceutically acceptable salt thereof refers to the free base of aspirin, pharmaceutically acceptable salt(s) of aspirin, and/or mixtures of the free base of aspirin and at least one pharmaceutically acceptable salt of aspirin.
- omeprazole or pharmaceutically acceptable salt thereof refers to the free base of omeprazole, pharmaceutically acceptable salt(s) of omeprazole, and/or mixtures of the free base of omeprazole and at least one pharmaceutically acceptable salt of omeprazole.
- unit dosage form or “unit dose form” as used herein refers to a single entity for drug administration. For example, a single tablet or capsule containing both an acid inhibitor and aspirin or a pharmaceutically acceptable salt thereof is a unit dosage form.
- Unit dosage forms of the present disclosure can provide for sequential drug release in a way that elevates gastric pH and reduces the deleterious effects of aspirin on the gastroduodenal mucosa, e.g., the acid inhibitor is released first and the release of aspirin is delayed until after the pH in the GI tract has risen to at least 3.5, 4.0, 4.5, 5.0, 5.5, or greater.
- a "unit dosage form” may also be referred to as a "fixed dosage form” or a "fixed dosage combination” and are otherwise interchangeable.
- the term “about” is intended to reflect variations from the specifically identified dosages that are acceptable within the art.
- the term “about” is intended to capture variations above and below the stated number that may achieve substantially the same results as the stated number.
- the term numerical values used in conjunction with the phrase “substantially free” the term is intended to capture variations above and below the stated number that may achieve substantially the same results as the stated number.
- the phrase “substantially free” means from about 95% to about 99.99% free.
- substantially free may mean about 95% free, about 96% free, about 97% free, about 98% free, about 99% free, or about 99.99% free.
- each of the variously stated ranges is intended to be continuous so as to include each numerical parameter between the stated minimum and maximum value of each range.
- a range of about 1 to about 4 includes about 1, 1, about 2, 2, about 3, 3, about 4, and 4.
- One embodiment is directed to a method comprising: treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to the patient in need thereof a pharmaceutical composition in unit dosage form comprising a) an acid inhibitor in an amount sufficient to raise the gastric pH of the patient to at least about 3.5, 4.0, 4.5, 5.0, 5.5, or greater upon administration of one or more of the unit dosage forms, and b) a therapeutically effective amount of aspirin, or a pharmaceutically acceptable salt thereof; wherein the unit dosage form provides for coordinated release of the acid inhibitor and the aspirin such that: i) at least a portion of the acid inhibitor is released independent of the pH of the surrounding medium; and ii) the aspirin, or a pharmaceutically acceptable salt thereof, is not released from the unit dosage form until the pH of the surrounding medium is at least about 3.5, 4.0, 4.5, 5.0, 5.5, or higher; and wherein the pharmaceutical composition in unit dosage form decreases the risk of the patient developing an ulcer.
- Another embodiment is directed to a method comprising: treating a disease or disorder in a patient in need of chronic NSAID treatment and at risk of developing an NSAID-associated ulcer by administering to the patient in need thereof a pharmaceutical composition in unit dosage form comprising a) an acid inhibitor in an amount sufficient to raise the gastric pH of the patient to at least about 3.5, 4.0, 4.5, 5.0, 5.5 or higher upon administration of one or more of the unit dosage forms, and b) a therapeutically effective amount of aspirin, or a pharmaceutically acceptable salt thereof; wherein the unit dosage form provides for coordinated release of the acid inhibitor and the aspirin such that: i) at least a portion of the acid inhibitor is released independent of the pH of the surrounding medium; and ii) the aspirin, or a pharmaceutically acceptable salt thereof, is not released from the unit dosage form until the pH of the surrounding medium is at least about 3.5, 4.0, 4.5, 5.0, 5.5 or higher; and wherein the pharmaceutical composition in unit dosage form decreases the risk of the
- Still another embodiment is directed to a method comprising: treating signs and symptoms of pain, inflammation, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, headache, toothache, common cold, muscle ache, cardiovascular disease, cancer, or any combination thereof in a patient at risk of developing an NSAID-associated ulcer by administering to the patient in need thereof a pharmaceutical composition in unit dosage form comprising a) an acid inhibitor in an amount sufficient to raise the gastric pH of the patient to at least about 3.5, 4.0, 4.5, 5.0, 5.5 or higher upon administration of one or more of the unit dosage forms, and b) a therapeutically effective amount of aspirin, or a pharmaceutically acceptable salt thereof; wherein the unit dosage form provides for coordinated release of the acid inhibitor and the aspirin such that: i) at least a portion of the acid inhibitor is released independent of the pH of the surrounding medium; and ii) the aspirin, or a pharmaceutically acceptable salt thereof, is not released from the unit dosage form until the pH
- Still yet another embodiment is directed to a method comprising: treating signs and symptoms of pain, inflammation, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, headache, toothache, common cold, muscle ache, cardiovascular disease, cancer, or any combination thereof in a patient in need of chronic NSAID treatment and at risk of developing an NSAID-associated ulcer by administering to the patient in need thereof a pharmaceutical composition in unit dosage form comprising a) an acid inhibitor in an amount sufficient to raise the gastric pH of the patient to at least about 3.5, 4.0, 4.5, 5.0, 5.5 or higher upon administration of one or more of the unit dosage forms, and b) a therapeutically effective amount of aspirin, or a pharmaceutically acceptable salt thereof; wherein the unit dosage form provides for coordinated release of the acid inhibitor and the aspirin such that: i) at least a portion of the acid inhibitor is released independent of the pH of the surrounding medium; and ii) the aspirin, or a pharmaceutically acceptable salt thereof, is
- the disease or disorder treated by the pharmaceutical compositions disclosed herein is selected from pain and inflammation.
- the disease or disorder treated by the pharmaceutical compositions disclosed herein is osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis.
- the disease or disorder treated by the pharmaceutical compositions disclosed herein is headache, toothache, common cold, muscle ache, cardiovascular disease, or any combination thereof.
- the disease or disorder treated by the pharmaceutical compositions disclosed herein is cancer.
- the patient at risk of developing an NSAID associated ulcer is > 50 years old.
- the patient at risk of developing an NSAID associated ulcer has a history of UGI ulcer or bleeding.
- the pharmaceutical composition in unit dosage form decreases the risk of the patient developing a gastroduodenal ulcer. In yet a further embodiment, the pharmaceutical composition in unit dosage form decreases the risk of the patient developing a duodenal ulcer. In a further embodiment, the pharmaceutical composition in unit dosage form decreases the risk of the patient developing a gastric ulcer.
- administering the pharmaceutical composition in unit dosage form of the present disclosure to patients in need of NSAID treatment results in fewer patients developing a gastric ulcer than patients in need of NSAID treatment who are administered aspirin, whether enteric coated or non-enteric coated aspirin.
- administering the pharmaceutical composition in unit dosage form of the present disclosure to patients in need of NSAID treatment results in fewer patients developing a duodenal ulcer than patients in need of NSAID treatment who are administered aspirin, whether enteric coated or non-enteric coated aspirin.
- administering the pharmaceutical composition in unit dosage form of the present disclosure to patients in need of NSAID treatment results in fewer patients developing heartburn associated symptoms than patients in need of NSAID treatment who are administered aspirin, whether enteric coated or non-enteric coated aspirin.
- administering the pharmaceutical composition in unit dosage form of the present disclosure to patients in need of NSAID treatment results in fewer patients developing dyspepsia than patients in need of NSAID treatment who are administered aspirin, whether enteric coated or non-enteric coated aspirin.
- administering the pharmaceutical composition in unit dosage form of the present disclosure to patients in need of NSAID treatment reduces the patents' level of urinary 11-dehydrothromboxane compared to patients in need of NSAID treatment who are administered aspirin, whether enteric coated or non-enteric coated aspirin.
- the patient is treated longer with the pharmaceutical composition in unit dosage form of the present disclosure than with aspirin, whether enteric coated or non- enteric coated aspirin.
- patient compliance with long-term treatment is improved with the pharmaceutical compositions disclosed herein as compared to aspirin, whether enteric coated or non-enteric coated aspirin.
- the pharmaceutical composition in unit dosage form is a multilayer tablet comprising at least one core and at least a first layer and a second layer, wherein: i) the core comprises aspirin, or a pharmaceutically acceptable salt thereof; ii) the first layer is a coating that at least begins to release the aspirin, or a pharmaceutically acceptable salt thereof, when the pH of the surrounding medium is about 3.5, 4.0, 4.5, 5.0, 5.5 or greater; and iii) the second layer comprises an acid inhibitor, wherein at least some of the acid inhibitor is released at a pH of from about 0 or greater, for example 0.5,
- the acid inhibitor is released from the multilayer tablet at a pH of from about 1.0 or greater. In a yet further embodiment, the acid inhibitor is released from the multilayer tablet at a pH of from about 0 to about 2.0. In a still further embodiment, at least a portion of the acid inhibitor contained in the multilayer tablet is not coated with an enteric coating. In a yet still further embodiment, the first layer of the multilayer tablet is an enteric coating or a time-release coating. In a yet even still further embodiment, the multi-layer tablet is substantially free of sodium bicarbonate. In a still further embodiment, the acid inhibitor is enantiomerically pure.
- the therapeutically effective amount of aspirin, or a pharmaceutically acceptable salt thereof, in the pharmaceutical compositions disclosed herein is selected from 30 mg and 1300 mg. In a still yet further embodiment, the therapeutically effective amount of aspirin, or a pharmaceutically acceptable salt thereof, is 81 mg. In a still yet further embodiment, the therapeutically effective amount of aspirin, or a pharmaceutically acceptable salt thereof, is 325 mg. In an even still further embodiment, the therapeutically effective amount of aspirin, or a pharmaceutically acceptable salt thereof, is 650 mg. In another embodiment, the therapeutically effective amount of aspirin, or a pharmaceutically acceptable salt thereof, is 75 mg, 100 mg, 150 mg, 162 mg, 300 mg, or 500 mg. In another embodiment, aspirin can be present as the free base. In yet another embodiment, aspirin can be present in equivalent amounts of pharmaceutically acceptable salts of aspirin.
- the pharmaceutical composition in unit dosage form comprises about 30-1300 mg of the aspirin, or a pharmaceutically acceptable salt thereof, and about 1-1000 mg of the acid inhibitor. In another embodiment, the pharmaceutical composition in unit dosage form comprises about 30-1300 mg of the aspirin, or a pharmaceutically acceptable salt thereof, and about 5-650 mg of a proton pump inhibitor. In another embodiment, the pharmaceutical composition in unit dosage form comprises about 30-1300 mg of the aspirin, or a pharmaceutically acceptable salt thereof, and about 5-50 mg omeprazole, or a pharmaceutically acceptable salt thereof, or about 15, 20, 30, or 40 mg omeprazole, or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition in unit dosage form comprises about 30- 1300 mg of the aspirin, or a pharmaceutically acceptable salt thereof, and about 5-100 mg esomeprazole, or a pharmaceutically acceptable salt thereof, or about 20, 30, or 40 mg esomeprazole, or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition in unit dosage form comprises about 30-1300 mg of the aspirin, or a pharmaceutically acceptable salt thereof, and about 10-150 lansoprazole, or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition in unit dosage form comprises about 30-1300 mg of the aspirin, or a pharmaceutically acceptable salt thereof, and about 10-200 pantoprazole, or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition in unit dosage form comprises about 30-1300 mg of the aspirin, or a pharmaceutically acceptable salt thereof, and about 15-100 mg dexlansoprazole, or a pharmaceutically acceptable salt thereof. In yet another embodiment, the pharmaceutical composition in unit dosage form comprises about 30-1300 mg of the aspirin, or a pharmaceutically acceptable salt thereof, and about 10-150 mg tenatoprazole, or a pharmaceutically acceptable salt thereof. In another embodiment, the pharmaceutical composition in unit dosage form comprises about 30-1300 mg of the aspirin, or a pharmaceutically acceptable salt thereof, and about 5-100 mg rabeprazole, or a pharmaceutically acceptable salt thereof, or about 20 mg rabeprazole, or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition in unit dosage form comprises about 81 mg of the aspirin, or a pharmaceutically acceptable salt thereof, and about 20 mg omeprazole, or a pharmaceutically acceptable salt thereof. In another embodiment, the pharmaceutical composition in unit dosage form comprises about 325 mg of the aspirin, or a pharmaceutically acceptable salt thereof, and about 20 mg omeprazole, or a pharmaceutically acceptable salt thereof. In still another embodiment, the pharmaceutical composition in unit dosage form comprises about 81 mg of the aspirin, or a pharmaceutically acceptable salt thereof, and about 40 mg omeprazole, or a pharmaceutically acceptable salt thereof.
- the pharmaceutical composition in unit dosage form comprises about 325 mg of the aspirin, or a pharmaceutically acceptable salt thereof, and about 40 mg omeprazole, or a pharmaceutically acceptable salt thereof. In one embodiment, the pharmaceutical composition in unit dosage form comprises about 650 mg of the aspirin, or a pharmaceutically acceptable salt thereof, and about 15 mg omeprazole, or a pharmaceutically acceptable salt thereof. In another embodiment, the pharmaceutical composition in unit dosage form comprises about 650 mg of the aspirin, or a pharmaceutically acceptable salt thereof, and about 20 mg omeprazole, or a pharmaceutically acceptable salt thereof. In yet another embodiment, the pharmaceutical composition in unit dosage form comprises about 650 mg of the aspirin, or a pharmaceutically acceptable salt thereof, and about 40 mg omeprazole, or a pharmaceutically acceptable salt thereof.
- the duration of treatment may be approximately 1 week, 10 days, 2 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months or longer, and may be chronic treatment.
- the pharmaceutical composition in unit dosage form is a multilayer tablet comprising a core comprising aspirin, or a pharmaceutically acceptable salt thereof, and a first layer comprising a coating that at least begins releasing the aspirin when the pH of the surrounding medium is about 3.5, 4.0, 4.5, 5.0, 5.5 or greater and a second layer comprising an acid inhibitor, wherein at least a portion of the acid inhibitor is not surrounded by an enteric coating.
- the multilayer tablet is substantially free of sodium bicarbonate. In still another embodiment, the multilayer tablet is completely (i.e., 100%) free of sodium bicarbonate.
- the dosing regimen of the pharmaceutical compositions disclosed herein is one or more times daily.
- the dosages are separated by a period of at least about 10 hours.
- the pharmaceutical composition in unit dosage form is given before a patient ingests a meal, for example about 30-60 minutes prior to ingesting a meal.
- the pharmaceutical compositions of the present disclosure may be administered therapeutically to patients either short term or over a longer period of time, for example chronically.
- compositions disclosed herein include, but are not limited to, for example, tablets and capsules that can be made in accordance with methods that are standard in the art (see, e.g., Remington's Pharmaceutical Sciences, 16 th ed., A Oslo editor, Easton, Pa. (1980)).
- Suitable carriers include, but are not limited to: water; salt solutions; alcohols; gum arabic; vegetable oils; benzyl alcohols; polyethylene glycols; gelatin; carbohydrates such as lactose, amylose or starch; magnesium stearate; talc; silicic acid; paraffin; perfume oil; fatty acid esters; hydroxymethylcellulose; polyvinyl pyrrolidone; carnauba wax, colloidal silicon dioxide, croscarmellose sodium, glyceryl monostearate, hypromellose, methacrylic acid copolymer dispersion, methylparaben, polysorbate 80, polydextrose, povidone, propylene glycol, propylparaben, titanium dioxide, and triethyl citrate.
- the layers comprising the pharmaceutical compositions disclosed herein may be applied using standard coating techniques.
- the layer materials may be dissolved or dispersed in organic or aqueous solvents.
- the layer materials may include, but are not limited to, for example, one or more of the following materials: methacrylic acid copolymers, shellac, hydroxypropylmethcellulose phthalate, polyvinyl acetate phthalate, hydroxypropylmethyl-cellulose trimellitate, carboxymethyl- ethyl-cellulose, cellulose acetate phthalate, and/or other suitable polymer(s).
- the pH at which the first layer dissolves can be controlled by the polymer or combination of polymers selected and/or ratio of pendant groups.
- dissolution characteristics of the polymer film can be altered by the ratio of free carboxyl groups to ester groups.
- the layers may also contain pharmaceutically acceptable plasticizers, such as, for example, triethyl citrate, dibutyl phthalate, triacetin, polyethylene glycols, polysorbates or other plasticizers.
- Additives may also be used in the pharmaceutical compositions disclosed herein, such as, for example, dispersants, colorants, anti-adhering, and anti-foaming agents.
- the pharmaceutical compositions disclosed herein can be in the form of a bi- or multi-layer tablet.
- a bi-layer tablet one portion/layer of the tablet contains the acid inhibitor, or a pharmaceutically acceptable salt thereof, in the required dosage along with any appropriate excipients, agents to aid dissolution, lubricants, fillers, and the like; and a second portion/layer of the tablet contains the aspirin or a pharmaceutically acceptable carrier thereof in the required dosage along with any excipients, dissolution agents, lubricants, fillers, and the like.
- the aspirin or a pharmaceutically acceptable carrier portion/layer is surrounded by a polymeric coating that dissolves at a pH of at least about 3.5, 4.0, 4.5, 5.0, 5.5 or greater.
- the aspirin or a pharmaceutically acceptable carrier portion/layer is surrounded by a coating that delays release until the pH of the surrounding environment is at least about 3.5, 4.0, 4.5, 5.0, 5.5 or greater.
- the aspirin, or a pharmaceutically acceptable salt thereof may be granulated by methods such as slugging, low- or high- shear granulation, wet granulation, or fluidized- bed granulation. Of these processes, slugging generally produces tablets of less hardness and greater friability. Low-shear granulation, high-shear granulation, wet granulation and fluidized-bed granulation generally produce harder, less friable tablets.
- Grade 3 or 4 Lanza scores and the incidences of GU/DU for the PA products were lower than for EC-ASA.
- Plasma salicylic acid pharmacokinetics were similar following dosing with PA32520 or PA32540 and EC-ASA 325 mg following both single-dose and repeat-dose administration.
- PA32520 was well tolerated and resulted in a similar frequency of GI adverse events as EC-ASA 325 mg.
- PA32520 induced less GI mucosal damage than EC- ASA 81 mg based on Grade 3 or 4 Lanza scores for the duodenum at Day 14 and duodenal erosion counts at Day 14.
- PA32520 was statistically significantly better than EC-ASA aspirin 81 mg in increasing mean gastric pH at Day 14 and Day 28, and increasing the proportion of subjects with gastric pH >3 at Day 14.
- PA32520 ECASA PA32520 ECASA
- the primary endpoint was Lanza Grade 3 or 4 (>20 erosions/hemorrhages or ulcers) at Day 28; secondary endpoints included Grade 3 or 4 at Day 14, gastric or duodenal ulcers by Day 28, and the change from baseline in urinary 1 l-dh-TXB 2 after 4 weeks. Study assessments were conducted at baseline, Day 14, and Day 28.
- PA32520 Treatment with EC-ASA alone is associated with a high prevalence of UGI damage that is ameliorated by PA32520 therapy. Compared to EC-ASA 81 mg, PA32520 produces superior inhibition of in vivo thromboxane generation. PA32520 may provide an important option for at patients treated with ASA, as well as the great patient population that takes ASA intermittently, for short-term therapy, or chronically. High-dose ASA in combination with proton pump inhibitors may provide a reduction in UGI damage and greater thromboxane suppression.
- EC-ASA 81 mg/day, l l-dh-TXB 2 was also measured.
- the endpoints were the proportion of subjects with Grade 3 or 4 Lanza scores at Day 14, the proportion of subjects with Grade 3 or 4 Lanza scores at Day 28, and the concentration of urinary 1 l-d-TXB 2 after 4 weeks of therapy.
- PA32540 was found to be bioequivalent to EC-ASA 325 mg/day; the geometric LSM ratio (90% CI) for AUCo- infinity was 1.095 (0.967, 1.239) and for C max was 1.077 (0.959, 1.209).
- Figure 3 shows the release profile of PA32540 at Day 13; IR omeprazole in PA32540 has no effect on the pharmacokinetic profile of salicylic acid. Omeprazole was rapidly absorbed from PA32540 and eliminated from the systematic circulation with a mean elimination half life of approximately 1 hour. Plasma exposure of salicylic acid from PA32540 was similar to marketed EC-ASA 325 mg following both single-dose and repeat- dose administration of PA32540.
- URINARY 11-D-TXB2 AFTER 4 WEEKS OF TREATMENT
- PA32540 is bioequivalent to EC-ASA 325 mg/day, but with a significant improvement in UGI safety. Also, PA32520 inhibits urinary l l-dh-TXB 2 significantly more than EC-ASA 81 mg/day. PA was associated with a significant reduction in gastroduodenal injury, and PA32540 demonstrated the least gastroduodenal damage and fewest overall GI adverse events. Thus, while secondary prevention of strokes and transient ischemic attacks with ASA alone is associated with UGI damage and as such may require lower doses of ASA or alternative anti-thrombotic agents, PA may allow for higher doses of ASA, for example for secondary prevention of cardiovascular disease, strokes and transient ischemic attacks.
- Phase 1 4-Week Endoscopic Study on PA65020 (Two Tablets of EC-ASA 325 mg + IR Omeprazole 20 mg) at Analgesic Doses that Shows Significant Reduction of Incidence of Gastroduodenal Ulcers
- Each dose of PA65020 was administered as one tablet of PA32520 and one tablet of EC-ASA 325 mg.
- EC-ASA 650 mg was administered as two EC-ASA 325 mg tablets.
- the total daily ASA dose was 1300 mg.
- Outcome evaluations included the occurrence of endoscopically proven gastric and/or duodenal lesions meeting Grade 3 or Grade 4 Lanza scores on Day 28 (primary endpoint), incidence of gastroduodenal ulcers, as well as assessments of dyspepsia-associated abdominal pain by mSODA (modified severity of dyspepsia assessment score, range 2-47), heartburn, and adverse events.
- a total of 40 subjects (mean age 59.7 years) were treated. As shown in Table 4, at Day 28, the incidence of Grade 3 or 4 Lanza scores was significantly less for the PA65020 group (3, or 15%) than for the EC-ASA 650 mg group (17, or 85%), PO.001.
- Analgesic doses of over-the-counter ASA produced significant mucosal damage in most subjects following 1 month of treatment.
- PA65020 is associated with a significantly decreased risk of GU/DU, and may provide an important option for at-risk patients who require analgesic doses of ASA.
- compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents that are chemically or physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2012000057A MX2012000057A (en) | 2009-06-25 | 2010-06-24 | Method for treating a patient in need of aspirin therapy. |
NZ597534A NZ597534A (en) | 2009-06-25 | 2010-06-24 | Method for treating a patient in need of aspirin therapy |
BRPI1012248A BRPI1012248A2 (en) | 2009-06-25 | 2010-06-24 | "method to treat a patient" |
JP2012517740A JP2012531430A (en) | 2009-06-25 | 2010-06-24 | Methods for treating patients in need of aspirin therapy |
CA2766524A CA2766524A1 (en) | 2009-06-25 | 2010-06-24 | Method for treating a patient in need of aspirin therapy |
EA201270071A EA021112B1 (en) | 2009-06-25 | 2010-06-24 | Method for treating pain and/or inflammation in a patient in need of aspirin therapy |
CN2010800375661A CN102638978A (en) | 2009-06-25 | 2010-06-24 | Method for treating a patient in need of aspirin therapy |
EP10792681A EP2445344A4 (en) | 2009-06-25 | 2010-06-24 | Method for treating a patient in need of aspirin therapy |
AU2010266026A AU2010266026B2 (en) | 2009-06-25 | 2010-06-24 | Method for treating a patient in need of aspirin therapy |
IL217198A IL217198A0 (en) | 2009-06-25 | 2011-12-25 | Composition for treating a patient in need of aspirin therapy |
ZA2012/00069A ZA201200069B (en) | 2009-06-25 | 2012-01-05 | Method for treating a patient in need of aspirin therapy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22048309P | 2009-06-25 | 2009-06-25 | |
US61/220,483 | 2009-06-25 | ||
US24875509P | 2009-10-05 | 2009-10-05 | |
US61/248,755 | 2009-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010151697A1 true WO2010151697A1 (en) | 2010-12-29 |
Family
ID=43386895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/039864 WO2010151697A1 (en) | 2009-06-25 | 2010-06-24 | Method for treating a patient in need of aspirin therapy |
Country Status (13)
Country | Link |
---|---|
US (2) | US20110008432A1 (en) |
EP (1) | EP2445344A4 (en) |
JP (2) | JP2012531430A (en) |
KR (1) | KR20120093140A (en) |
CN (1) | CN102638978A (en) |
AU (1) | AU2010266026B2 (en) |
CA (1) | CA2766524A1 (en) |
EA (1) | EA021112B1 (en) |
IL (1) | IL217198A0 (en) |
MX (1) | MX2012000057A (en) |
NZ (1) | NZ597534A (en) |
WO (1) | WO2010151697A1 (en) |
ZA (1) | ZA201200069B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8852636B2 (en) | 2001-06-01 | 2014-10-07 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
JP2014533656A (en) * | 2011-11-30 | 2014-12-15 | 武田薬品工業株式会社 | Dry-coated tablets |
US8945621B2 (en) | 2009-06-25 | 2015-02-03 | Pozen Inc. | Method for treating a patient at risk for developing an NSAID-associated ulcer |
US9220698B2 (en) | 2008-09-09 | 2015-12-29 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
US9539214B2 (en) | 2011-12-28 | 2017-01-10 | Pozen Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103239724A (en) * | 2013-05-27 | 2013-08-14 | 成都自豪药业有限公司 | Anti-thrombosis combined drug and pharmaceutical composition thereof |
CN105530946A (en) * | 2013-09-11 | 2016-04-27 | 南加利福尼亚大学 | A composition of stem cells having highly expressed fas ligand |
CN103941007A (en) * | 2014-03-28 | 2014-07-23 | 瑞莱生物科技(江苏)有限公司 | Immunofluorescence test strip for fast and quantitatively detecting curative effect of aspirin and preparation method of immunofluorescence test strip |
KR102255308B1 (en) * | 2014-11-18 | 2021-05-24 | 삼성전자주식회사 | Composition for preventing or treating a side effect of steroid in a subject compprising acetylsalicylic acid and use thereof |
US9218978B1 (en) * | 2015-03-09 | 2015-12-22 | Cypress Semiconductor Corporation | Method of ONO stack formation |
AU2020396554A1 (en) * | 2019-12-05 | 2022-07-07 | Flagship Pioneering Innovations V, Inc. | Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020160046A1 (en) * | 2000-11-29 | 2002-10-31 | Robinson Joseph R. | Delivery system for omeprazole and its salts |
US20040022846A1 (en) * | 1996-01-08 | 2004-02-05 | Helene Depui | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID |
US6869615B2 (en) * | 2000-09-11 | 2005-03-22 | Andrx Labs Llc | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
US20050249811A1 (en) * | 2001-06-01 | 2005-11-10 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US20070237820A1 (en) * | 2004-01-21 | 2007-10-11 | Andrx Pharmaceuticals, Llc | Pharmaceutical formulations containing a non-steroidal antinflammatory drug and an antiulcerative drug |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7804231L (en) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Gastric acid secretion |
CH647676A5 (en) * | 1978-12-22 | 1985-02-15 | Donald E Panoz | ORAL, PROGRAM RELEASED GALENIC FORMS AND METHODS OF PREPARING THE SAME. |
US4198390A (en) * | 1979-01-31 | 1980-04-15 | Rider Joseph A | Simethicone antacid tablet |
US4344929A (en) * | 1980-04-25 | 1982-08-17 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
SE8301182D0 (en) * | 1983-03-04 | 1983-03-04 | Haessle Ab | NOVEL COMPOUNDS |
IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
US4766117A (en) * | 1984-10-11 | 1988-08-23 | Pfizer Inc. | Antiinflammatory compositions and methods |
US4676984A (en) * | 1985-08-14 | 1987-06-30 | American Home Products Corp. | Rehydratable antacid composition |
CA1327010C (en) * | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
US4757060A (en) * | 1986-03-04 | 1988-07-12 | Bristol-Myers Company | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers |
US5043358A (en) * | 1986-03-04 | 1991-08-27 | Bristol-Myers Squibb Company | Gastroprotective process |
US5037815A (en) * | 1986-03-04 | 1991-08-06 | Bristol-Myers Squibb Co. | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers |
GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
JPH0768125B2 (en) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | Oral formulation of acid labile compounds |
US4948581A (en) * | 1989-02-17 | 1990-08-14 | Dojin Iyaku-Kako Co., Ltd. | Long acting diclofenac sodium preparation |
US5204118A (en) * | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
ATE121625T1 (en) * | 1990-05-03 | 1995-05-15 | Searle & Co | PHARMACEUTICAL COMPOSITION. |
JP3016829B2 (en) * | 1990-07-13 | 2000-03-06 | 王子油化合成紙株式会社 | Coated resin film with excellent offset printability |
US5409709A (en) * | 1991-11-29 | 1995-04-25 | Lion Corporation | Antipyretic analgesic preparation containing ibuprofen |
US6875872B1 (en) * | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
SE9301830D0 (en) * | 1993-05-28 | 1993-05-28 | Ab Astra | NEW COMPOUNDS |
DK66493D0 (en) * | 1993-06-08 | 1993-06-08 | Ferring A S | PREPARATIONS FOR USE IN TREATMENT OF INFLAMMATORY GAS DISORDERS OR TO IMPROVE IMPROVED HEALTH |
SE9302396D0 (en) * | 1993-07-09 | 1993-07-09 | Ab Astra | A NOVEL COMPOUND FORM |
US5514663A (en) * | 1993-10-19 | 1996-05-07 | The Procter & Gamble Company | Senna dosage form |
WO1995011024A1 (en) * | 1993-10-19 | 1995-04-27 | The Procter & Gamble Company | Picosulphate dosage form |
US6025395A (en) * | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
US5643960A (en) * | 1994-04-15 | 1997-07-01 | Duke University | Method of delaying onset of alzheimer's disease symptoms |
US5750531A (en) * | 1994-08-13 | 1998-05-12 | Yuhan Corporation | Pyrimidine derivatives and processes for the preparation thereof |
SE9500478D0 (en) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
US20050054682A1 (en) * | 1996-01-04 | 2005-03-10 | Phillips Jeffrey O. | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same |
US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
SE9600071D0 (en) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
US6231888B1 (en) * | 1996-01-18 | 2001-05-15 | Perio Products Ltd. | Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps |
US5872145A (en) * | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
US6077539A (en) * | 1996-11-12 | 2000-06-20 | Pozen, Inc. | Treatment of migraine headache |
SE510650C2 (en) * | 1997-05-30 | 1999-06-14 | Astra Ab | New association |
SE510643C2 (en) * | 1997-06-27 | 1999-06-14 | Astra Ab | Thermodynamically stable omeprazole sodium form B |
CA2301883A1 (en) * | 1997-09-11 | 1999-03-18 | Nycomed Danmark A/S | Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids) |
US6326028B1 (en) * | 1997-10-31 | 2001-12-04 | Monsanto Company | Alginate and gellan gum as tablet coating |
SE9704870D0 (en) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
FR2772615B1 (en) * | 1997-12-23 | 2002-06-14 | Lipha | MULTILAYER TABLET FOR INSTANT RELEASE THEN PROLONGED ACTIVE SUBSTANCES |
AU742620B2 (en) * | 1998-01-30 | 2002-01-10 | Sepracor, Inc. | R-lansoprazole compositions and methods |
US6093734A (en) * | 1998-08-10 | 2000-07-25 | Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin | Prodrugs of proton pump inhibitors |
US6387410B1 (en) * | 1998-09-10 | 2002-05-14 | Norton Healthcare Ltd | Anti-inflammatory pharmaceutical formulations |
US8231899B2 (en) * | 1998-09-10 | 2012-07-31 | Nycomed Danmark Aps | Quick release pharmaceutical compositions of drug substances |
US6713089B1 (en) * | 1998-09-10 | 2004-03-30 | Nycomed Danmark A/S | Quick release pharmaceutical compositions of drug substances |
US20020090395A1 (en) * | 1998-09-10 | 2002-07-11 | Austen John Woolfe | Anti-inflammatory pharmaceutical formulations |
ID28275A (en) * | 1998-09-28 | 2001-05-10 | Warner Lambert Co | COLON AND ENTERIC DELIVERY USING HPMC CAPSULES |
SE9803772D0 (en) * | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
DE19901687B4 (en) * | 1999-01-18 | 2006-06-01 | Grünenthal GmbH | Opioid controlled release analgesics |
US6183779B1 (en) * | 1999-03-22 | 2001-02-06 | Pharmascience Inc. | Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin |
PT1165044E (en) * | 1999-03-26 | 2004-10-29 | Pozen Inc | HIGH POWER DI-HYDRO-PYROTAMINE COMPOUNDS |
US20020044962A1 (en) * | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
SE0002476D0 (en) * | 2000-06-30 | 2000-06-30 | Astrazeneca Ab | New compounds |
US7029701B2 (en) * | 2000-09-11 | 2006-04-18 | Andrx Pharmaceuticals, Llc | Composition for the treatment and prevention of ischemic events |
US20020045184A1 (en) * | 2000-10-02 | 2002-04-18 | Chih-Ming Chen | Packaging system |
SE0101379D0 (en) * | 2001-04-18 | 2001-04-18 | Diabact Ab | Composition that inhibits gastric acid secretion |
MXPA03011017A (en) * | 2001-06-01 | 2005-04-29 | Pozen Inc | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs. |
US20100172983A1 (en) * | 2001-06-01 | 2010-07-08 | Plachetka John R | Pharmaceutical Compositions for the Coordinated Delivery of Naproxen and Esomeprazole |
US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
US20040131676A1 (en) * | 2002-12-20 | 2004-07-08 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
US20070243251A1 (en) * | 2002-12-20 | 2007-10-18 | Rajneesh Taneja | Dosage Forms Containing A PPI, NSAID, and Buffer |
AU2003303631B2 (en) * | 2002-12-26 | 2008-05-29 | Nuvo Pharmaceuticals (Ireland) Designated Activity Company | Multilayer Dosage Forms Containing NSAIDs and Triptans |
CA2517005A1 (en) * | 2003-02-20 | 2004-09-02 | Santarus, Inc. | A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
JP2005145894A (en) * | 2003-11-17 | 2005-06-09 | Takeda Chem Ind Ltd | Solid preparation |
CA2554271A1 (en) * | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
US20060165797A1 (en) * | 2005-01-12 | 2006-07-27 | Pozen Inc. | Dosage form for treating gastrointestinal disorders |
US20060178348A1 (en) * | 2005-01-24 | 2006-08-10 | Pozen Inc. | Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an NSAID |
US20060178349A1 (en) * | 2005-01-24 | 2006-08-10 | Pozen Inc. | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID |
US20060177504A1 (en) * | 2005-02-08 | 2006-08-10 | Renjit Sundharadas | Combination pain medication |
WO2007036809A2 (en) * | 2005-05-24 | 2007-04-05 | Flamel Technologies S.A. | Novel acetylsalicylic acid formulations |
AR057181A1 (en) * | 2005-11-30 | 2007-11-21 | Astra Ab | NEW COMBINATION DOSAGE FORM |
US20070154542A1 (en) * | 2005-12-30 | 2007-07-05 | Cogentus Pharmaceuticals, Inc. | Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors |
CA2660648A1 (en) * | 2006-06-15 | 2007-12-21 | Novartis Ag | Compositions and methods for treating diseases |
MX2009004475A (en) * | 2006-10-27 | 2009-08-12 | Univ Missouri | Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same. |
US20080031950A1 (en) * | 2007-04-27 | 2008-02-07 | Nectid Inc. | Novel anelgesic combination |
CA2736547C (en) * | 2008-09-09 | 2016-11-01 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
US8189555B2 (en) * | 2009-02-06 | 2012-05-29 | Qualcomm Incorporated | Communications methods and apparatus for supporting communications with peers using multiple antenna patterns |
-
2010
- 2010-06-24 EA EA201270071A patent/EA021112B1/en not_active IP Right Cessation
- 2010-06-24 AU AU2010266026A patent/AU2010266026B2/en not_active Ceased
- 2010-06-24 NZ NZ597534A patent/NZ597534A/en not_active IP Right Cessation
- 2010-06-24 CA CA2766524A patent/CA2766524A1/en not_active Abandoned
- 2010-06-24 JP JP2012517740A patent/JP2012531430A/en active Pending
- 2010-06-24 MX MX2012000057A patent/MX2012000057A/en unknown
- 2010-06-24 WO PCT/US2010/039864 patent/WO2010151697A1/en active Application Filing
- 2010-06-24 US US12/823,082 patent/US20110008432A1/en not_active Abandoned
- 2010-06-24 EP EP10792681A patent/EP2445344A4/en not_active Withdrawn
- 2010-06-24 KR KR1020127001816A patent/KR20120093140A/en not_active Application Discontinuation
- 2010-06-24 CN CN2010800375661A patent/CN102638978A/en active Pending
-
2011
- 2011-12-25 IL IL217198A patent/IL217198A0/en unknown
-
2012
- 2012-01-05 ZA ZA2012/00069A patent/ZA201200069B/en unknown
- 2012-01-06 US US13/345,075 patent/US20120177736A1/en not_active Abandoned
-
2015
- 2015-12-28 JP JP2015255645A patent/JP2016104778A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040022846A1 (en) * | 1996-01-08 | 2004-02-05 | Helene Depui | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID |
US6869615B2 (en) * | 2000-09-11 | 2005-03-22 | Andrx Labs Llc | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
US20020160046A1 (en) * | 2000-11-29 | 2002-10-31 | Robinson Joseph R. | Delivery system for omeprazole and its salts |
US20050249811A1 (en) * | 2001-06-01 | 2005-11-10 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US20070237820A1 (en) * | 2004-01-21 | 2007-10-11 | Andrx Pharmaceuticals, Llc | Pharmaceutical formulations containing a non-steroidal antinflammatory drug and an antiulcerative drug |
Non-Patent Citations (1)
Title |
---|
See also references of EP2445344A4 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9707181B2 (en) | 2001-06-01 | 2017-07-18 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US8858996B2 (en) | 2001-06-01 | 2014-10-14 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDS |
US8865190B2 (en) | 2001-06-01 | 2014-10-21 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US8852636B2 (en) | 2001-06-01 | 2014-10-07 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US9161920B2 (en) | 2001-06-01 | 2015-10-20 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US9198888B2 (en) | 2001-06-01 | 2015-12-01 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US9345695B2 (en) | 2001-06-01 | 2016-05-24 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US9364439B2 (en) | 2001-06-01 | 2016-06-14 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US9801824B2 (en) | 2008-09-09 | 2017-10-31 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
US9220698B2 (en) | 2008-09-09 | 2015-12-29 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
US9393208B2 (en) | 2008-09-09 | 2016-07-19 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
US8945621B2 (en) | 2009-06-25 | 2015-02-03 | Pozen Inc. | Method for treating a patient at risk for developing an NSAID-associated ulcer |
US9433632B2 (en) | 2011-11-30 | 2016-09-06 | Takeda Pharmaceutical Company Limited | Dry coated tablet |
JP2014533656A (en) * | 2011-11-30 | 2014-12-15 | 武田薬品工業株式会社 | Dry-coated tablets |
US10238605B2 (en) | 2011-11-30 | 2019-03-26 | Takeda Pharmaceutical Company Limited | Dry coated tablet |
US9539214B2 (en) | 2011-12-28 | 2017-01-10 | Pozen Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
US9987231B2 (en) | 2011-12-28 | 2018-06-05 | Pozen Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
US10603283B2 (en) | 2011-12-28 | 2020-03-31 | Genus Lifesciences, Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
Also Published As
Publication number | Publication date |
---|---|
EP2445344A4 (en) | 2013-01-23 |
MX2012000057A (en) | 2012-06-01 |
KR20120093140A (en) | 2012-08-22 |
AU2010266026A1 (en) | 2012-02-02 |
EA201270071A1 (en) | 2012-08-30 |
EA021112B1 (en) | 2015-04-30 |
IL217198A0 (en) | 2012-02-29 |
AU2010266026B2 (en) | 2014-08-07 |
CN102638978A (en) | 2012-08-15 |
US20110008432A1 (en) | 2011-01-13 |
JP2016104778A (en) | 2016-06-09 |
NZ597534A (en) | 2013-09-27 |
ZA201200069B (en) | 2017-11-29 |
US20120177736A1 (en) | 2012-07-12 |
CA2766524A1 (en) | 2010-12-29 |
EP2445344A1 (en) | 2012-05-02 |
JP2012531430A (en) | 2012-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2010266026B2 (en) | Method for treating a patient in need of aspirin therapy | |
EP1411900B2 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs | |
US8945621B2 (en) | Method for treating a patient at risk for developing an NSAID-associated ulcer | |
CA2860231A1 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
NO327245B1 (en) | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an NSAID, method of preparation and use thereof. | |
JP2012531430A5 (en) | ||
CA2503211C (en) | Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent | |
WO2004062552A2 (en) | Pharmaceutical composition containing a nsaid and a benzimidazole derivative | |
US20130064891A1 (en) | Pharmaceutical compositions of nsaid and acid inhibitor | |
JP2019532960A (en) | Esomeprazole-containing composite capsule and method for producing the same | |
US20090022786A1 (en) | Oral pharmaceutical dosage form and manufacturing method thereof | |
KR102289011B1 (en) | Oral sustained-release combined formulation comprising NSAIDs and a proton pump inhibitor | |
CA2740974A1 (en) | Dosage forms for the rapid and sustained elevation of gastric ph | |
EP2015731A2 (en) | Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic- analgesic drug and proton pump inhibitor | |
WO2019135725A1 (en) | Combinations of selective cox-2 inhibitor nsaids and h2 receptor antagonists for fast treatment of pain and inflammation | |
KR20150114657A (en) | Pharmaceutical compositions and a method for manufacturing containing Ilaprazole and nonsteroidal anti-inflammatory drug or pharmaceutically acceptable salt | |
Scarpignato et al. | Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments | |
US20190307713A1 (en) | Combinations of diclofenac and h2 receptor antagonists for the treatment of pain and inflammation | |
KR20230149188A (en) | Pharmaceutical composition comprising acetylsalicylic acid and proton pump inhibitor | |
Dore et al. | Naproxen/esomeprazole magnesium in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis | |
WO2018231176A2 (en) | Combinations of diclofenac and h2 receptor antagonists for the treatment of pain and inflammation | |
WO2019240310A1 (en) | Complex formulation comprising aceclofenac and esomeprazole and method of preparing same | |
WO2020018048A2 (en) | An immediate release pharmaceutical composition of anti-inflammatory drugs, famotidine and a carbonate | |
WO2018231175A2 (en) | Non-steroidal anti-inflammatory drugs and h2 receptor antagonist combinations for treatment of pain and inflammation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080037566.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10792681 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012517740 Country of ref document: JP Ref document number: 2766524 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/000057 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010792681 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010266026 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20127001816 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 815/CHENP/2012 Country of ref document: IN Ref document number: 201270071 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2010266026 Country of ref document: AU Date of ref document: 20100624 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1012248 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1012248 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111223 |